Concept Life Sciences (“Concept”), the integrated drug discovery and development and analytical services company, today announced the expansion of its regulatory GLP (good laboratory practice) capabilities at the Group’s Dundee and Bradford sites.
Manchester and Dundee, UK, Concept Life Sciences (“Concept”), the integrated drug discovery and development and analytical services company, today announced the expansion of its regulatory GLP (good laboratory practice) capabilities at the Group’s Dundee and Bradford sites. The MHRA has confirmed the extension of Dundee’s in vitro capabilities to cover a range of additional assays, and Bradford can now offer a range of integrated GLP regulatory studies to further support pharmaceuticals, medical devices and healthcare.
The breadth of services offered to customers at all stages of discovery and development now also covers compounds going through pre- and post-clinical regulation studies, eventually up to IND. In addition to its original non-regulatory services, the Company’s regulatory offering now includes a wide range of assays for enzyme activity, microsomal inhibition, metabolite identification, and cell culture, including hepatocyte induction studies.
The extension forms part of a phased plan to expand GXP compliance (including GLP and GMP) at Concept’s facilities across the UK. Concept’s GXP compliance plan will increase the services it offers for the manufacture of API (active pharmaceutical ingredient) material, and enable the Group to further support the development of compounds from the discovery stage to full IND packages, providing increased assurance of data integrity and compliance with international standards to ensure acceptance of data by global regulatory bodies.
John Handley, Chief Operating Officer, Concept Life Sciences, said: “The extension of our GLP accreditation by the MHRA in both Dundee and Bradford enables us to further expand the growing portfolio of services we offer to our clients. The accreditations reflect Concept’s ongoing strategy to implement GXP compliance across multiple sites, and to grow as a company.”
ENDS
For a high-resolution image please contact Zyme Communications
Media contacts
For Concept Life Sciences
Katie Odgaard
Zyme Communications
E: katie.odgaard@zymecommunications.com
T: +44 (0)7787 502 947
To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.
About Concept Life Sciences www.conceptlifesciences.com
Concept Life Sciences provides integrated, high quality discovery, development and analytical services to the AgChem, Chemical, Pharmaceutical and Biotech sectors. Formed as a result of targeted acquisition and organic growth, the Company has the in-house expertise and resource to support customers with projects spanning from target discovery to the clinic, adding value and IP throughout the discovery pathway.
With a track record of delivering knowledge-based, science-led solutions, the Company employs over 700 FTEs, including more than 500 highly skilled, experienced scientists, supporting its global client base from 11 state of the art laboratory facilities.
Having experienced rapid growth, Concept Life Sciences remains focused on problem solving, quality, collaboration, and flexibility. In January 2018, Concept Life Sciences became an Operating Company of Spectris plc.
About GLP
GLP refers to a quality system of management controls to ensure uniformity, consistency, reliability, reproducibility, quality and integrity in non-clinical laboratory studies and gives confidence in the safety assessment of a compound. GLP applies to the pharmaceutical industry and the required non-clinical animal testing that must be performed prior to approval of new drug products, and also to many other non-pharmaceutical agents such as colour additives, food additives, food contamination limits, food packaging, and medical devices.
